Opendata, web and dolomites

HypoRuLight

Hypoxic Tumour Models for Photoactivatable Ruthenium-based Chemotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "HypoRuLight" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT LEIDEN 

Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ
website: www.universiteitleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 150˙000.00

Map

 Project objective

In this Proof-of-Concept project I will show the commercial potential of ruthenium-based photoactivated chemotherapy (PACT) compounds developed in my ERC Starting Grant by demonstrating their efficacy on hypoxic cancer models. Photoactivated chemotherapy is a new class of phototherapy to treat cancer. In principle, PACT looks similar to photodynamic therapy (PDT): light irradiation of the tumour in vivo leads to local activation of the anticancer prodrug, thereby limiting the toxicity of the treatment to the diseased tissue, and thus lowering side effects for the patient. However, the mechanisms of PACT and PDT are very different: in PDT the light-absorbing prodrug requires molecular oxygen to kill the cancer cells, whereas in PACT oxygen is not involved in prodrug activation. As a consequence, PACT agents should be able to treat hypoxic tumours, which are characterized by low oxygen concentrations and high resistance to PDT and other existing therapies. In this project the efficacy of a selection of Ru-based PACT compounds will be tested in hypoxic cancer models and compared to their efficacy in normoxic conditions. In parallel I will develop, in collaboration with my network of collaborators from the clinics, business analysts, and patent attorney, a plan for (pre) clinical development of PACT compounds.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPORULIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPORULIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More